Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

NCT05875025 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucociliary Clearance

Interventions

OTHER: Placebo formulated with HFA-152a propellant via pMDI
OTHER: Placebo formulated with HFA-134a propellant via pMDI

Sponsor

Chiesi Farmaceutici S.p.A.